|
An open-label, multicenter, randomized, controlled study of an investigational drug in postmenopausal women with advanced breast cancer (ABC) having progressed on Tamoxifen. Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, trips or professional assistance with a real medical doctor. We aren't docs. Always confer with your doctor about An open-label, multicenter, randomized, controlled study of an investigational drug in postmenopausal women with advanced breast cancer (ABC) having progressed on Tamoxifen. conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. An open-label, multicenter, randomized, controlled study of an investigational drug in postmenopausal women with advanced breast cancer (ABC) having progressed on Tamoxifen. Clinical research trials and An open-label, multicenter, randomized, controlled study of an investigational drug in postmenopausal women with advanced breast cancer (ABC) having progressed on Tamoxifen. health trials happen in many of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectualness of new does drugs. The intention of the studies / projects is to figure out particular human healthcare questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to detect cures for all forms of circumstances, like An open-label, multicenter, randomized, controlled study of an investigational drug in postmenopausal women with advanced breast cancer (ABC) having progressed on Tamoxifen.. An open-label, multicenter, randomized, controlled study of an investigational drug in postmenopausal women with advanced breast cancer (ABC) having progressed on Tamoxifen. Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment options before they are available to the general public. Most times the subjects get treatment for free of charge, and occasionally they are paid for their time. Occasionally there is a cost for a An open-label, multicenter, randomized, controlled study of an investigational drug in postmenopausal women with advanced breast cancer (ABC) having progressed on Tamoxifen. clinical trial. Subjects frequently get the best healthcare possible for their An open-label, multicenter, randomized, controlled study of an investigational drug in postmenopausal women with advanced breast cancer (ABC) having progressed on Tamoxifen. condition. Hazards are a reality, however, and could include more or frequent mD visits, health risks (possibly life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > An open-label, multicenter, randomized, controlled study of an investigational drug in postmenopausal women with advanced breast cancer (ABC) having progressed on Tamoxifen.  An open-label, multicenter, randomized, controlled study of an investigational drug in postmenopausal women with advanced breast cancer (ABC) having progressed on Tamoxifen.
An open-label, multicenter, randomized, controlled study of an investigational drug in postmenopausal women with advanced breast cancer (ABC) having progressed on Tamoxifen.
For Condition: Metastases, Neoplasm,Breast Neoplasms
Status: Terminated
Sponsor(s): Pfizer ,
Synopsis: The purpose of this study is to find out if the two different formulations of an investigational drug, oral and injectable, are equivalent in terms of pharmacodynamics and pharmacokinetics, i.e. if ultimately both formulations have the same efficacy in postmenopausal women with metastatic breast cancer who have failed previous antiestrogens therapy and are equally safe.
Details:
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: /
Genders: Female
Protocol Entry Criteria: Other specific inclusion/exclusion criteria may apply. In order to determine eligibility, further examination by the investigator is necessary. Inclusion Criteria: Diagnosed with breast cancer Estrogen receptor positivity Postmenopausal status Advanced disease Progression to previous tamoxifen therapy Exclusion Criteria: More than 1 chemotherapy and-or more than 1 hormonotherapy for advanced disease Previous hormonotherapy other than Tamoxifen
Total Enrollment:
Location and Contact Information:
Research Center
Puyallup, Washington, 98372
United States
Research Center
Yakima, Washington, 98902
United States
Research Center
St. Louis, Missouri, 63136
United States
Additional Information:
Study ID Numbers: 971-ONC-0401-003;
Study Start Date:
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00040014
Other Breast Neoplasms Studies:
1. Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer
2. A Phase 3 Trial of ALIMTA (LY231514, pemetrexed) plus GEMZAR Versus GEMZAR in Patients with Unresectable or Metastatic Cancer of the Pancreas.
3. A Phase II Clinical Trial of ABI-007, Administered Weekly in Taxol Resistant Patients with Metastatic Breast Cancer
4. Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel
5. Evaluation of Bay 59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients
Related Studies:
Other Breast Neoplasms Clinical Trials
Other Washington Clinical Trials
Other Yakima Clinical Trials
An open-label, multicenter, randomized, controlled study of an investigational drug in postmenopausal women with advanced breast cancer (ABC) having progressed on Tamoxifen.
|
|
|
|
|
|
|
|
